and read my last post from the most recent issue of Clinical Liver Diseases.
You guys throw around lots of dirt here, but you really understand little as to what's going on. In the race for advanced fibrosis cases it's Gilead and Galt with two different approaches- that could potentially be synergistic one day.
Arun Sanyal is one of the most foremost respected Hepatologists in the world. Galt's approach may or may not work. But if it does, the pps is 100X it's current price.
I will take those odds.
Future Treatment of NASH
Another approach is to take those with advanced fibrosis and focus on the fibrosis. The rationale for this approach is that this may prevent hepatic decompensation and liver-related outcomes, including death. It may also buy time for other approaches directed at the steatohepatitis itself to work. There is currently a multinational phase 2b/3 trial of a monoclonal antibody to lysl-oxidase that is ongoing. A phase 1 trial of a Galectin-antibody has also been completed without evidence of toxicity. Numerous other fibrosis targets are currently also being evaluated in early-phase trials (see ClinicalTrials.gov for a list of such agents).
Ultimately, it is hoped that a diverse array of agents which are safe and attack a variety of molecular targets will be available for the treatment of NASH. Improvement in noninvasive and molecular pathology methods will allow identification of the molecular targets relevant for a given individual and permit treatment to be tailored to the individual. Although much work remains to be done, there is considerable optimism and excitement, which provides hope that this vision of personalized medicine will be actualized to control this modern epidemic.
may just be a ploy to get MSFT to buy HERE
Big poker game going on